ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 مارس 2025 07:00:05 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 فبراير 2025 06:59:55 بحسب Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 فبراير 2025 06:50:01 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 يناير 2025 16:01:21 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 يناير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 ديسمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 نوفمبر 2024 09:45:01 بحسب NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

18 نوفمبر 2024 09:52:02 بحسب NetDania Notify

Aclaris Therapeutics Announces $80 Million Private Placement

18 نوفمبر 2024 08:10:41 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 نوفمبر 2024 08:10:04 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

13 نوفمبر 2024 09:53:10 بحسب NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

11 نوفمبر 2024 09:48:00 بحسب NetDania Notify

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

06 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

07 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

16 يوليو 2024 16:01:43 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

06 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

07 مايو 2024 16:01:00 بحسب Nasdaq GlobeNewswire